Consumer

Investing in Scribenote

Olivia Moore and Anish Acharya Posted September 23, 2024

Veterinarians face many critical daily decisions, but one in particular during every appointment. 

Do you give the pet (and owner) your full focus, leaving hours of work at the end of the day as you try to recall and type up the visit notes? Or do you document the visit while performing the exam — resulting in more accurate notes (and less after-hours work), but at the expense of your focus and bedside manner?

Scribenote makes this trade-off obsolete. As the market-leading AI scribe for veterinarians, Scribenote allows vets to simply press a button at the beginning of an appointment and let AI do the work. Afterwards, Scribenote provides a properly formatted set of SOAP (Subjective, Objective, Assessment, and Plan) notes, plus the transcript and recording. This includes bespoke workflows for specific and complex appointment types, like dental exams. 

Scribenote automates burdensome documentation requirements, so vets can focus on the parts of the job they love. Vets, like human doctors, have extremely high burnout rates: almost 90% report burnout scores in the “moderate” or “high” range in the U.S. A tool that helps vets manage their workloads can be life-changing for both the providers and their patients. In addition, Scribenote saves clinics time and money in headcount or staff turnover. 

An estimated 66% of Americans now own a pet — and spending on those pets nearly tripled over the last decade. Expectations for the quality of pet care have never been higher, yet vet clinics have also never been more constrained and understaffed, making it crucial to equip vets with tools that make their jobs easier. 

The Scribenote team has deep empathy for the daily challenges veterinarians face and a hands-on understanding of their workflow. Cofounder Ryan Gallagher spent hours shadowing his veterinarian sister, Katie, in an effort to help her get home on time. Scribenote started as Ryan’s senior capstone project at the University of Waterloo with cofounder Alina Pavel. The two built the product quietly for three years, until the tech was finally ready to deliver at scale — and passed the bar for Katie to use in her own appointments. 

Over the last year, Scribenote has grown to serve thousands of vets per month, many of whom use Scribenote for every appointment. These customers range from independent vets to large clinic chains and corporate groups with hundreds of clinicians. Vets love Scribenote for its ease, with nuances and details that are specific to their day-to-day. 

We’re excited to announce our investment in Scribenote and partner with them on their mission to build technology that improves the lives of vets. If you’re a veterinarian or manage a clinic and want to try the product for yourself, learn more at Scribenote.com.

Want More a16z Consumer?

Analysis and news covering the latest trends reshaping B2C and consumer tech.

Learn More
Recommended For You
Fintech

new Investing in Lio

Seema Amble, James da Costa, Eric Zhou, and Brian Roberts
Bio + Health

new Investing in Ease

Daisy Wolf, Anish Acharya, and Eva Steinman
Infra

Investing in QuiverAI

Yoko Li, Guido Appenzeller, and Martin Casado
American Dynamism

Investing in Chariot Defense

Erin Price-Wright and Ryan McEntush
American Dynamism

Investing in Heron Power

Erin Price-Wright and Ryan McEntush

Want More Consumer?

Analysis and news covering the latest trends reshaping B2C and consumer tech.

Sign Up On Substack

Views expressed in “posts” (including podcasts, videos, and social media) are those of the individual a16z personnel quoted therein and are not the views of a16z Capital Management, L.L.C. (“a16z”) or its respective affiliates. a16z Capital Management is an investment adviser registered with the Securities and Exchange Commission. Registration as an investment adviser does not imply any special skill or training. The posts are not directed to any investors or potential investors, and do not constitute an offer to sell — or a solicitation of an offer to buy — any securities, and may not be used or relied upon in evaluating the merits of any investment.

The contents in here — and available on any associated distribution platforms and any public a16z online social media accounts, platforms, and sites (collectively, “content distribution outlets”) — should not be construed as or relied upon in any manner as investment, legal, tax, or other advice. You should consult your own advisers as to legal, business, tax, and other related matters concerning any investment. Any projections, estimates, forecasts, targets, prospects and/or opinions expressed in these materials are subject to change without notice and may differ or be contrary to opinions expressed by others. Any charts provided here or on a16z content distribution outlets are for informational purposes only, and should not be relied upon when making any investment decision. Certain information contained in here has been obtained from third-party sources, including from portfolio companies of funds managed by a16z. While taken from sources believed to be reliable, a16z has not independently verified such information and makes no representations about the enduring accuracy of the information or its appropriateness for a given situation. In addition, posts may include third-party advertisements; a16z has not reviewed such advertisements and does not endorse any advertising content contained therein. All content speaks only as of the date indicated.

Under no circumstances should any posts or other information provided on this website — or on associated content distribution outlets — be construed as an offer soliciting the purchase or sale of any security or interest in any pooled investment vehicle sponsored, discussed, or mentioned by a16z personnel. Nor should it be construed as an offer to provide investment advisory services; an offer to invest in an a16z-managed pooled investment vehicle will be made separately and only by means of the confidential offering documents of the specific pooled investment vehicles — which should be read in their entirety, and only to those who, among other requirements, meet certain qualifications under federal securities laws. Such investors, defined as accredited investors and qualified purchasers, are generally deemed capable of evaluating the merits and risks of prospective investments and financial matters.

There can be no assurances that a16z’s investment objectives will be achieved or investment strategies will be successful. Any investment in a vehicle managed by a16z involves a high degree of risk including the risk that the entire amount invested is lost. Any investments or portfolio companies mentioned, referred to, or described are not representative of all investments in vehicles managed by a16z and there can be no assurance that the investments will be profitable or that other investments made in the future will have similar characteristics or results. A list of investments made by funds managed by a16z is available here: https://a16z.com/investments/. Past results of a16z’s investments, pooled investment vehicles, or investment strategies are not necessarily indicative of future results. Excluded from this list are investments (and certain publicly traded cryptocurrencies/ digital assets) for which the issuer has not provided permission for a16z to disclose publicly. As for its investments in any cryptocurrency or token project, a16z is acting in its own financial interest, not necessarily in the interests of other token holders. a16z has no special role in any of these projects or power over their management. a16z does not undertake to continue to have any involvement in these projects other than as an investor and token holder, and other token holders should not expect that it will or rely on it to have any particular involvement.

With respect to funds managed by a16z that are registered in Japan, a16z will provide to any member of the Japanese public a copy of such documents as are required to be made publicly available pursuant to Article 63 of the Financial Instruments and Exchange Act of Japan. Please contact compliance@a16z.com to request such documents.

For other site terms of use, please go here. Additional important information about a16z, including our Form ADV Part 2A Brochure, is available at the SEC’s website: http://www.adviserinfo.sec.gov.